Human papillomavirus type 16 (HPV16) is a major risk for development of oropharyngeal squamous-cell-carcinoma (OPSCC). Although HPV 1 OPSCC metastasize faster than HPV 2 tumors, they have a better prognosis. The molecular and cellular altera- Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has been recognized as a unique subset of head and neck squamous cell carcinomas (HNSCC). HPV infection has been implicated as a major causative factor in OPSCC with HPV16 by far being the most frequent HPV type involved. 1 There seems to be a strong correlation between tumor development and infection frequency, with numbers varying between 36% and 90%. [2] [3] [4] [5] HPV associated OPSCC has proven to differ from alcohol and tobacco associated OPSCC in regard to the molecular pathophysiology, presentation, epidemiology, prognosis and improved response to chemoradiation.
Human papillomavirus type 16 (HPV16) is a major risk for development of oropharyngeal squamous-cell-carcinoma (OPSCC). Although HPV 1 OPSCC metastasize faster than HPV 2 tumors, they have a better prognosis. The molecular and cellular alterations underlying this pathobiology of HPV 1 OPSCC remain elusive. In this study, we examined whether expression of HPV16-E6E7 targets the number of migratory and stationary cancer stem cells (CSC). Furthermore, we wanted to elucidate if aberrantly expressed miRNAs in migratory CSC may be responsible for progression of OPSCCs and whether they may serve as potential novel biomarkers for increased potential of metastasis. Our studies revealed that HPV16-E6E7 expression leads to an increase in the number of stationary (CD44 RT-qPCR and in situ hybridization on HPV16 1 OPSCCs. These experiments led to the identification of miR-3194-5p, which is upregulated in primary HPV16 1 OPSCC and matched metastasis. MiR-1281 was also found to be highly expressed in HPV 1 and HPV 2 metastasis. As inhibition of this miRNA led to a markedly reduction of CD44 high /EpCAM low cells, it may prove to be a promising drug target. Taken together, our findings highlight the capability of HPV16 to modify the phenotype of infected stem cells and that miR-1281 and miR3194-5p may represent promising targets to block metastatic spread of OPSCC.
Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has been recognized as a unique subset of head and neck squamous cell carcinomas (HNSCC). HPV infection has been implicated as a major causative factor in OPSCC with HPV16 by far being the most frequent HPV type involved. 1 There seems to be a strong correlation between tumor development and infection frequency, with numbers varying between 36% and 90%. [2] [3] [4] [5] HPV associated OPSCC has proven to differ from alcohol and tobacco associated OPSCC in regard to the molecular pathophysiology, presentation, epidemiology, prognosis and improved response to chemoradiation. 6 However, these tumors have a higher risk for metastasis, 7 which indicates an essential role of HPV in carcinogenic processes, possibly driven by an increase in the number of tumor-initiating cells or cancer stem cells (shortly CSC). CSCs have the capacity to self-renew, maintain an undifferentiated cell phenotype, are resistant to therapy 8 and re-establish tumor heterogeneity upon recurrence or metastasis. 9 It is interesting to note that phenotypic heterogeneity and plasticity of CSCs was observed to be associated with epithelial-mesenchymal transition (EMT), which promotes metastasis. In addition, CSCs possess the capacity to switch between epithelial and mesenchymal phenotypes and thus have the ability to undergo both EMT and mesenchymal to epithelial transition (MET). EMT and MET also play important roles in stem cell differentiation and de-differentiation. 10 Therefore, targeting migratory CSC populations in OPSCC in particular should be a high priority in the development of effective cancer therapies. The proof that EMT and non-EMT CSCs co-exist in pathologic tissues and cancer cell lines may help to identify potentially relevant new targets for therapeutic interventions intended to halt tumor recurrence and metastatic spreading.
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MicroRNA (miRNA) expression profiling has revealed patterns implicated in tumor development and progression. [12] [13] [14] [15] Aberrant expression of miRNAs in HPV-positive (HPV 1 ) OPSCC has recently been shown. [16] [17] [18] However, a detailed understanding of miRNA expression profiles in CSC populations of HPV 1 OPSCC is lacking. The aim of this study was to unravel a possible association between HPV16 oncogene expression and migratory CSCs and a possible role of miRNAs in the control of stem cell characteristics.
Materials and Methods

Cell culture
The human tongue squamous cell carcinoma cell line H357 (STNMP stage I) 19 was maintained in RM1 medium (consisting of a 3:1 ratio of Dulbecco's modified Eagle's medium (DMEM) and DMEM/F-12 with 10% fetal calf serum (FCS), 1% glutamine, 0.4 lg hydrocortisone, 10-10 M cholera toxin, 5 lg/ml transferrin, 2 3 10-11 M liothyronine, 5 lg/ml insulin, 10 ng/ml epidermal growth factor, 13 penicillinstreptomycin mixture). PT67 cell line were maintained in DMEM with 10% FCS and penicillin-streptomycin mixture. H357 cells were tested for authentication by the German Biological Resource Centre DSMZ (Braunschweig, Germany) and confirmed to be HPV negative using the bead-based multiplex genotyping method. 20 A pool of human foreskin keratinocytes (HFK) of 4 donors were purchased from Lonza (Cologne, Germany) and grown in KGM-Gold media (Lonza). Cell cultures were incubated at 378C in a humidified 6% CO 2 atmosphere.
Retroviral expression vectors and infection of keratinocytes
The generation of the pLXSN-16E6E7 plasmid was previously described in Halbert et al. (1992) . 21 Production of retroviruses and retroviral infection of keratinocytes was performed as described in Refs. 22,23. Selection of infected primary keratinocytes or H357 cells started 2 days following transduction using cell culture medium supplemented with G418. Positive clones were pooled and expanded. 
Transfection of miRNA inhibitors in keratinocytes
FACS analysis and cell sorting
Fluorescence-activated cell sorting (FACS) analysis and cell sorting was performed as described in Hufbauer et al.
. 23 Cells cultured in cell culture flasks were detached using enzyme-free, phosphate-buffered saline (PBS)-based cell dissociation buffer (Invitrogen, Darmstadt, Germany). Fresh tumor specimens that were not required for pathological analyses were obtained immediately after biopsy or surgical removal and were processed as described previously 24 . Staining of cells was performed for CD44 (clone G44-26, BD Biosciences, Oxford, United Kingdom) and EpCAM (Cat. No. 130-091-254, Miltenyi Biotec, Bergisch Gladbach, Germany) in order to measure their respective cell surface expression. Overall cell viability was verified by using DAPI (4 0 ,6 0 -diamidino-2-phenylindole) or 7-AAD (7-amino-actinomycin D; BioLegend, San Diego, CA). Before cell sorting, cells were filtered through a 30-lm filter (Miltenyi Biotec). Cell analysis was carried out with a MACSQuant analyzer (Miltenyi Biotec) and cell sorting using a FACSAria (BD Biosciences). FACS profiles of transduced cells did not show any significant changes in CD44/EpCAM cell surface levels after different time-points (1-4 weeks) after selection in G418 (data not shown).
RNA isolation, reverse transcription and real-time PCR
Total RNA from sorted CD44 high /EpCAM low and CD44 high / EpCAM high H357 cells or fresh OPSCC was isolated as described in Hufbauer et al. (2011) . 25 Polyadenylation and reverse transcription of miRNA was performed using the miScript II RT-Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. To quantify miRNA levels quantitative reverse transcription (RT-qPCR) using the LightCycler system (Roche, Mannheim, Germany) and the miScript SYBR Green PCR kit (Qiagen) were performed as recommended in the manufacturer's protocol. Reverse transcription and RT-qPCR of mRNA was performed as described in Ref. 26 . RT-qPCR analyses were carried out in duplicates in three independent experiments and normalized to the housekeeping genes SNORA11b, SNORA38, U49a and U96a for miRNA or HPRT1 for mRNA analyses. The x-fold change in miRNA expression was calculated using the mathematical model introduced by Pfaffl et al. (2001) . 27 For mRNA analysis a dilution series of a standard plasmid was used to determine absolute changes. The sequences of the PCR-primers are shown in Supporting Information, Table 1 .
Patient material and ethics statement
Patient material was used according to the code for proper secondary use of human tissue. The ethics committee of the University of Cologne approved this study (approved protocol no. 11-346) and written informed consent was obtained from all patients prior to any study-related procedure. Formalin-fixed, paraffin-embedded OPSCC samples from 21 patients including 10 primary tonsillar tumors with corresponding metastasis were obtained at the time of surgical resection. 28 All patients were treated at the Department of Otorhinolaryngology and Head and Neck Surgery of the University Hospital of Cologne, Germany, between 1997 and 2010. Table 1 summarizes the clinicopathological features of the OPSCC cases used in this study. Fresh tumor specimens used for FACS experiments were obtained from patients with previously untreated OPSCC. Together with additional control cases derived from tonsillectomy, all samples were collected from the archive of the Department of Pathology, University Hospital of Cologne, Germany.
HPV typing by PCR and immunohistochemistry
DNA was isolated from formalin-fixed, paraffin embedded tissue using the Gentra puregene tissue kit including proteinase K treatment (Qiagen) according to the manufacturer's instructions. Quality of extracted DNA was tested by betaGlobin gene PCR using PCO4/GH20 primers. 3 For HPV detection, GP51/61 PCR was performed. 29 Following purification (QIAquick PCR Purification kit, Qiagen) positive PCR products were sequenced (GATC Biotech, Konstanz, Germany) utilizing the GP51 primer. Sequencing results were analyzed using the BLASTN program. Immunohistochemical staining was performed on formaldehyde-fixed, paraffinembedded tissue sections of 5 mm thickness using a monoclonal mouse anti-human p16INK4A antibody (Clone G175-405; BD Biosciences; Cat. No. 550834). The antibody was detected by avidin-biotin-peroxidase complex (ABC) method employing the Vectastain-Elite-ABC kit (Vector Laboratories; Cat. No. PK-6100). Diaminobenzidine tetrahydrochloride/ H 2 O 2 was used to visualize peroxidase activity and hematoxylin to counterstain nuclei. Strong cytoplasmic and nuclear staining was regarded as positive staining.
In situ hybridization
The labeling of the LNA detection probes against miRNA196b, 21281, 23194-5p, 24763-5p (Exiqon) was performed using the DIG Oligonucleotide 3 0 -End Labeling Kit "2nd Generation" (Roche, Mannheim, Germany) as described in the manufacturer's manual. In situ hybridisation of 4 mm sections of HPV16 1 and HPV 2 paraffin-embedded surgical tissue specimens of OPSCCs, as well as native tonsils was performed as described in Chikh et al. (2011) . 30 The slides were developed using DAB peroxidase substrate kit Infectious Causes of Cancer (Vector Laboratories, CA). After counterstaining with hematoxylin (Sigma-Aldrich, Taufkirchen, Germany), slides were dehydrated by washing them in increasing concentrations of ethanol, then mounted in DePeX mounting medium (Serva, Heidelberg, Germany) and visualized with a Zeiss Axiophot microscope and imaging software. Staining intensity was quantified by three independent observers (MM, MH, CH) and consensus was achieved in case of interobserver discrepancy.
MiRNA microarray
One microgram total RNA from sorted H357 pLXSN CD44 high / EpCAM low and H357 pLXSN-16E6E7 CD44 high /EpCAM low were analyzed in a comparative Affymetrix GeneChip miRNA 3.0 microarray at the Cologne Center for Genomics based on the Sanger mirBase (release v17). Microarrays were performed with RNA from three independent cell sorts for each cell fraction. Raw data was pre-processed in Affymetrix Expression Console. Differential miRNA level expression was analyzed with the Transcriptome Analysis Console (Affymetrix).
Statistical analysis
All experiments were repeated a minimum of three times. All data from RT-qPCRs were expressed as mean 6 SD. The data presented as images of in situ hybridization analysis are from representative experiments, which was qualitatively similar in the replicate experiments. Statistical significance was determined with paired/unpaired two-tailed Student's t test. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Results
HPV16-E6E7 expression affects keratinocyte stem cell populations
To investigate whether HPV16-E6E7 oncogene expression has an effect on the stem cell compartment characterized by CD44 and EpCAM cell surface expression, first a pool of (Fig. 1a) . Using the same experimental setup, HPV16-E6E7 expressing H357 cells (oral cancer cell line) were generated and oncogene expression was confirmed by RT-qPCR (Supporting Information, Fig. 1 ). The parental cell line (originally obtained from a tongue carcinoma) showed distinct subpopulations of CD44 positive cells with different clonogenic activity, which can also be observed in freshly isolated biopsies of HNSCC. 31 The CD44 high /EpCAM high population was previously identified as proliferative and retained epithelial characteristics (non-EMT, stationary stem cells), whereas the CD44 high /EpCAM low fraction was migratory and had mesenchymal traits characteristic of EMT stem cells. 10 The number of cells with a CD44 high /EpCAM high immunophenotype did not change significantly in HPV16-E6E7 positive H357 cells. However, HPV16-E6E7 expression led to a 2-fold increase (p 5 0.0037) in cells with CD44 high /EpCAM low levels (Fig.  1b) . These data suggest that HPV16-E6E7, depending on the transformation status of the transgenic keratinocytes, can modulate the cell surface levels of CD44 and EpCAM. This may result in an increase of stationary stem cells in HFK In contrast the expression of the epithelial markers E-cadherin and calgranulin B was significantly downregulated (Fig. 1c) OPSCCs could be detected (Fig. 2c) . These results confirmed the clinical relevance of our in vitro findings in H357 cells. Also, they provide evidence that HPV16 oncogene expression may facilitate the emergence of migratory CSC cells in OPSCCs.
Differential regulation of miRNA expression in HPV16
1 migratory stem cells
In previous studies, miRNAs were identified as promising prognostic and diagnostic biomarkers of OPSCCs. [16] [17] [18] However, there are no existing data on changes in miRNA expression in HPV16 1 stationary and migratory stem cell populations. To provide a detailed understanding on HPV16-E6E7 mediated regulation of miRNAs, we performed a comparative miRNA microarray screen with total RNA extracted from the sorted CD44 high /EpCAM low fraction of H357-pLXSN and H357-HPV16-E6E7 cells. Microarrays were performed with RNA from three independent cell sorts, which were used in three independent microarray experiments. Out of 1,719 detected miRNAs, 14 were found to be >2.5-fold differentially regulated in the migratory stem cell population of H357 pLXSN-16E6E7 cells (CD44 high /EpCAM low cells) compared to the control cells (7 upregulated and 7 downregulated; Table 2 ). To confirm miRNA deregulation, reversely transcribed RNA was analysed in RT-qPCR experiments. The levels of miR-548ac, 2548aj, 23128 and 23201 were found to be below detection threshold. In contrast to microarray prediction, altered expression of miR-27a*, 230a*, 2183, 2224, 21208 and 21292 could not be confirmed by RT-qPCR. However, a significant upregulation of miR-1281 (3.82-fold; p 5 0.007), 23194-5p (1.98-fold; p 5 0.004) and 
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24763-5p (2.07-fold; p < 0.0001) as well as a significant downregulation of miR-196b (0.6-fold; p 5 0.0004) could be determined in the CD44 high /EpCAM low fraction of H357-HPV16-E6E7 cells compared to the corresponding cell fraction of H357-pLXSN cells (Fig. 3a) . Interestingly, in cells with CD44 high /EpCAM high immunophenotype the expression levels of miR-196b, 21281, 23194-5p and 24763-5p were found not to be affected by HPV16-E6E7 (Fig. 3b) . The differential expression of these four miRNAs could finally be confirmed in the CD44 high /EpCAM low subpopulation of FACS-sorted fresh OPSCC samples. These results indicated that the HPV16-mediated increase of migratory stem cells may be associated with altered miRNA expression patterns. Table 2 ). Staining of tonsillar mucosa for miR-3194-5p revealed no or weak expression. Most interestingly, whereas HPV 2 primary OPSCCs and metastasis showed no or only weak staining for miR-3194-5p, strong expression could be detected in HPV16 1 primary
OPSCCs as well as corresponding metastasis (Fig. 4d and Supporting Information, Table 2 ). To finally prove a direct correlation of miRNA expression on OPSCC sections with known distribution of CD44 Fig. 2 ).
Inhibition of miR-1281 in HPV16-E6E7 positive cells leads to changes in CD44/EpCAM cell surface expression
To determine a direct link between CSC and miR-1281 or miR-3194-5p, which were identified to be differentially expressed in primary OPSCCs, miRNA inhibitor experiments were performed. H357 cells were transfected with miRNA inhibitors against miR-1281 or miR-3194-5p and analyzed for (Fig. 5b) . This data indicated that the HPV16-E6E7 target miR-1281 may be involved in the regulation of migratory and stationary stem cell pools. Since no experimentally proven targets of miR-1281 are known, we performed in silico analysis and identified DRIM (down-regulated in metastasis protein) by five different computer prediction tools (miRTarBase, MirMap, miRWalk, miRDB, Targetscan) as a predicted metastasis associated target. Strikingly, DRIM mRNA expression levels were found to be significantly reduced in CD44 high /EpCAM low cells of HPV 1 compared to HPV 2 OPSCCs (Fig. 5c ). 
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Discussion
There is emerging evidence that CSCs are highly resistant to chemotherapy suggesting that CSCs may be responsible for disease relapse and progression. [35] [36] [37] The study by Biddle et al. (2011) mesenchymal EMT phenotype. Therefore CD44 together with EpCAM represent appropriate cell surface markers to distinguish between a stationary and migratory CSC phenotype. Taken together, our findings imply that HPV16 oncogene expression in HFK may initially lead to an increase in the number of stationary stem cells. However, it can be speculated that following accumulation of certain genetic alterations over time that facilitate the progression of these cells to transformed stationary CSCs, HPV16 oncogenes may then allow for the emergence of migratory EMT-CSCs. However, it is not clear yet, whether CD44 high /EpCAM low cells originate from the transformation of normal tissue stem cells. This time-dependent transformation of the stem cell populations by HPV16 might therefore be relevant for the speed of metastatic spread. The enhanced therapeutic response of HPV-related OPSCC in response to chemotherapy might be linked to HPV-dependent apoptosis.
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HPV16
1 OPSCC is considered a distinct molecular and clinical entity with a better response to radiotherapy and overall survival compared to HPV 2 cases. 40 Related to these observations, Zhang et al. (2014) demonstrated that HPV16 1 OPSCC have a higher intrinsic CSC population than HPV 2 OPSCC and a twofold increased tumorigenicity in vivo. The authors therefore concluded that the CSC phenotype might be more critical regarding overall disease prognosis than the absolute number of CSC. 41 Interestingly, using freshly 
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isolated tumor material we found an about two-fold rise in the number of EMT-CSCs in HPV 1 OPSCC compared to HPV 2 cancers. This rise may thus be an explanation for the higher metastatic potential of HPV 1 OPSCCs. It still needs to be determined how the microanatomy of the crypt epithelium of tonsils with its incomplete basal cell layer and discontinuing basement membrane may contribute to the tendency of lymphogenic metastasis in HPV related OPSCC, which is still matter of discussions. 42 All previous studies on miRNA expression in HNSCC analyzed the global miRNA profile and did not focus on expression changes in CSC (sub)populations. [43] [44] [45] [46] [47] To determine a possible role of certain miRNAs in the regulation of
HPV16
1 stationary and migratory oral/oropharyngeal stem cell populations, we characterized miRNA regulation in HPV16-E6E7 positive and negative EMT-CSCs. We show that HPV16-E6E7 positive EMT-CSCs display changes in their miRNA expression profile. We could confirm differential regulation of mir-196b, 21281, 23194-5p and 24763-5p in the CD44 high /EpCAM low cell fraction of HPV16 1 H357 cells as well as HPV16 1 fresh OPSCC. To verify these findings from monolayer cultures we used miRNA in situ hybridization of primary tonsillar cancer and matched metastasis. MiRNA-196b and miR-4763-5p expression levels were found to be upregulated in both primary OPSCCs and matched metastasis, albeit with no significant difference between 
1 and HPV 2 tumors as predicted by the microarray results. These controversial results may be explained by differences in expression under in vitro or in vivo conditions. Recently it could be shown that overexpressed miR-196b plays a crucial role in modulating cell migration and invasion during oral SCC progression and thus may serve as a potential prognostic marker or therapeutic target for oral SCC. 48 1 OPSCCs (described in Fig. 2 ) by RT-qPCR and normalized to HPRT1 mRNA levels. Error bars represent the standard deviation.
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